ReviewJournal of innate immunity2026
Neutrophil CEACAMs and the Inflammatory Response to
Review in Journal of innate immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCarcinoembryonic antigen-related cell adhesion molecules (CEACAMs) are proteins that mediate intercellular adhesion, intracellular signaling, and microbial recognition. Of the CEACAMs made by human neutrophils, CEACAMs 1, 3, and 6 are receptors for opacity-associated (Opa) outer membrane proteins of the bacterial pathogen Neisseria gonorrhoeae, which drive their non-opsonic phagocytosis. SUMMARY: This review describes what is currently known about CEACAM subcellular localization, bacterial recognition, and downstream signaling events in human neutrophils in response to N. gonorrhoeae and the experimental systems used to elucidate them. It highlights the consequences of these activities on neutrophil activation and killing of N. gonorrhoeae, particularly those downstream of CEACAM3. The potential cross-talk between CEACAMs and with other neutrophil receptors, and how these signals may impact responses to N. gonorrhoeae, are also covered. KEY MESSAGES: Most Opa proteins of N. gonorrhoeae bind CEACAM1, with a subset also binding CEACAM3. Neutrophil CEACAM binding stimulates signaling events that drive phagocytosis of Opa-expressing N. gonorrhoeae, accompanied by degranulation, oxidant production, and proinflammatory signaling and transcriptional responses. In particular, CEACAM3 ligation leads to rapid phagocytic killing of N. gonorrhoeae. N. gonorrhoeae can avoid CEACAM3-mediated clearance by phase variation to turn off Opa protein expression or producing non-CEACAM3-binding Opa proteins. It can also bind host-derived complement C4b-binding protein (C4BP) and sialic acid, to impede CEACAM3-Opa interaction and engage sialic acid-binding immunoglobulin-like lectins (Siglecs) that transduce inhibitory signals to dampen CEACAM3 signaling, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.